Article Per Year (5 Year)
p-Index From 2021 - 2026
0.444
P-Index
This Author published in this journals
All Journal Indonesian Journal of Clinical Pathology and Medical Laboratory (IJCPML)
Mas Aditya Senaputra
Department Of Clinical Pathology, Faculty Of Medicine, Sebelas Maret University/Dr. Moewardi General Academic Hospital, Surakarta
Biochemistry, Genetics & Molecular Biology Health Professions Medicine & Pharmacology Neuroscience

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Diagnostic Performance of Precore Protein 22 Kilodalton Levels of HBV DNA in Chronic Hepatitis B Patients Mas Aditya Senaputra; B. Rina A. Sidharta; Lusi Oka Wardhani
INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY Vol. 29 No. 3 (2023)
Publisher : Indonesian Association of Clinical Pathologist and Medical laboratory

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24293/ijcpml.v29i3.2020

Abstract

Hepatitis B Virus (HBV) infection causes inflammation of the liver, which has a high prevalence in both Indonesia and the world. Serum HBV deoxyribonucleic acid (DNA) is important in determining the initiation therapy for Chronic Hepatitis B (CHB) patients. However, it has several limitations. Precore protein 22 kilodalton (p22cr) is synthesized from the HBV gene in hepatocytes, representing covalently closed circle (ccc) DNA. This study aimed to analyze the diagnostic performance of p22cr levels on HBV DNA in CHB patients. An observational analytic study with a cross-sectional approach was conducted on 83 CHB patients who were examined at the Clinical Pathology Laboratory of Dr. Moewardi General Academic Hospital in December 2020. Blood plasma samples were taken for HBV DNA and p22cr examination by using Polymerase Chain Reaction (PCR) and Enzyme-Linked Immunosorbent Assay (ELISA), respectively. The cut-off level of p22cr was determined by the Receiver Operating Curve (ROC) with the widest area Under the Curve (AUC). Sensitivity, specificity, Positive Predictive Value (PPV), Negative Predictive Value (NPV), Positive Likelihood Ratio (PLR), Negative Likelihood Ratio (NLR), and accuracy were calculated for the diagnostic performance of p22cr. The cut-off point of p22cr on HBV DNA > 20,000 IU/mL was 7.440 ng/mL with AUC 0.693 (p=0.003). The diagnostic performance of p22cr levels on HBV DNA obtained 44.44% sensitivity, 82.98% specificity, 66.67% PPV, 66.10% NPV, 2.61 PLR, 0.67 NLR, and 66.27% accuracy. P22cr level has a good specificity so it can be an alternative examination of HBV DNA in making decisions on therapy in patients with chronic hepatitis B. Further research needs to be done using HBcrAg and excluding elderly patients.
Humoral and Cellular Immune Response on COVID-19 Patients and Sinovac Vaccine Participants Brigitte Rina Aninda Sidharta; Mas Aditya Senaputra
INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY Vol. 30 No. 2 (2024)
Publisher : Indonesian Association of Clinical Pathologist and Medical laboratory

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24293/ijcpml.v30i2.2061

Abstract

Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 is a new SARS-CoV virus. A person who is infected with this virus will induce both humoral and cellular immune responses. Herd immunity can be achieved through vaccination. The purpose of vaccination is the formation of antibodies capable of neutralizing coronavirus against the receptor binding domain. This study aimed to determine the differences between humoral and cellular immune responses between confirmed COVID-19 patients and Sinovac vaccine participants. This observational analytic study with a prospective cohort approach was conducted between March to October 2021. Fifty subjects (25 officers who had received vaccinations for COVID-19 patients and 25 COVID-19 patients treated at the Dr. Moewardi General Hospital) and met the inclusion and exclusion criteria were enrolled. Different tests were carried out to see the difference between the levels of CD8+ T cells and anti-SARS-CoV-2 antibodies in the vaccine group and the COVID-19 patient group. There was no significant difference in humoral immune response (anti-SARS-CoV-2) between the vaccine group and COVID-19 patient group [33.93 (0.4–196.6) U/L vs. 101.28±158.59 U/L; p=0.409], but there was a significant difference in cellular immune response (CD8+) between the vaccine group and COVID-19 patient group [878.52±47368 cells/µL vs. 270.16±213.64 cells/µL; p=0.001]. CD8 assay can be used as a parameter to differentiate the cellular immune response between COVID-19 patients and COVID-19 vaccine recipients.
Co-Authors B. Rina A. Sidharta Brigitte Rina Aninda Sidharta Lusi Oka Wardhani